Physicians support school-based vaccinations

January 13th 2025

Food Insecurity and the Dangers of Infant Formula Dilution

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).

January 30th 2023

Addictive behaviors surrounding social media could lead to binge eating

January 10th 2025

Demystifying Infant Formula

Results from a recent study revealed that compulsive and addictive elements can contribute to the risk of disordered eating. Study investigator Susan Carnell, PhD, explains these findings.

October 11th 2022

New data: Viaskin Peanut patch improves treatment benefit through 36 months

CDC: 2024-2025 seasonal norovirus outbreaks up from previous years

In an open-label extension of the EPITOPE phase 3 trial, the Viaskin Peanut patch had continued improvement in toddlers aged 1-3 years through 36 months.

PDUFA date set for neffy 1 mg for children who weigh 33 lbs or more

Based on reports by NoroSTAT-participating states, the total number of outbreaks in 2024-2025 seasonal year is above the range reported 012–2020 and 2021-2024 seasonal years.

Related Content

January 13th 2025

Food Insecurity and the Dangers of Infant Formula Dilution

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).

January 30th 2023

Addictive behaviors surrounding social media could lead to binge eating

January 10th 2025

Demystifying Infant Formula

Results from a recent study revealed that compulsive and addictive elements can contribute to the risk of disordered eating. Study investigator Susan Carnell, PhD, explains these findings.

October 11th 2022

New data: Viaskin Peanut patch improves treatment benefit through 36 months

CDC: 2024-2025 seasonal norovirus outbreaks up from previous years

In an open-label extension of the EPITOPE phase 3 trial, the Viaskin Peanut patch had continued improvement in toddlers aged 1-3 years through 36 months.